Kaleido Current Assets Trend from 2010 to 2022

KLDO -  USA Stock  

USD 1.89  0.21  10.00%

Kaleido Biosciences Current Assets yearly trend continues to be quite stable with very little volatility. Current Assets may rise above about 62.3 M this year. From the period between 2010 and 2022, Kaleido Biosciences, Current Assets regression line of its data series had standard deviation of 18,824,967 and standard deviation of  18,824,967. Kaleido Biosciences Interest Expense is quite stable at the moment as compared to the past year. The company's current value of Interest Expense is estimated at 3.48 Million. Weighted Average Shares is expected to rise to about 41.5 M this year, although the value of Consolidated Income will most likely fall to (79.3 M).

Kaleido Historical Trends 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 3.5 M or Operating Expenses of 85.1 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.76 or Current Ratio of 3.93. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Biosciences Quarterly Current Assets

58.3 MillionShare

Kaleido Current Assets Breakdown

Showing smoothed Current Assets of Kaleido Biosciences with missing and latest data points interpolated. Current assets of Kaleido Biosciences include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Kaleido Biosciences. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.Kaleido Biosciences' Current Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kaleido Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 72.93 M10 Years Trend
Increasing
Slightly volatile
 Current Assets 
Share
      Timeline 

Kaleido Current Assets Regression Statistics

Arithmetic Mean 41,922,663
Geometric Mean 38,581,096
Coefficient Of Variation 44.90
Mean Deviation 16,457,432
Median 28,551,000
Standard Deviation 18,824,967
Range 47,692,000
R-Value 0.74
R-Squared 0.55
Significance 0.003894
Slope 3,572,635

Kaleido Current Assets History

201876.2 M
201973.3 M
202048.7 M
202156 M
202262.3 M

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's Current Assets, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Current Assets56 M62.3 M
Average Assets82.3 M88.3 M
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Kaleido Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kaleido Biosciences. If investors know Kaleido will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kaleido Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.